Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168576 | 1.00 | NLRP3 (0.47) | NLRP3AKR1B1GPR139ALOX15ALDH1A1 | |
| SCHEMBL24076914 | 0.87 | GAA (0.50) | NLRP3GPR139ALOX15ALDH1A1GAA | |
| SCHEMBL24077038 | 0.86 | NLRP3 (0.47) | NLRP3GPR139ALOX15 | |
| SCHEMBL24076916 | 0.86 | LMNA (0.42) | NLRP3AKR1B1GPR139ALDH1A1GAA | |
| SCHEMBL24077044 | 0.84 | NLRP3 (0.50) | NLRP3AKR1B1GPR139ALOX15ALDH1A1 | |
| SCHEMBL25746221 | 0.83 | RAB9A (0.52) | NLRP3AKR1B1GPR139ALOX15ALDH1A1 | |
| SCHEMBL24077179 | 0.83 | NLRP3 (0.49) | NLRP3AKR1B1ALOX15GAAKDM4E | |
| SCHEMBL24077399 | 0.83 | NLRP3 (0.45) | NLRP3AKR1B1GPR139ALOX15KMT2A | |
| SCHEMBL24076314 | 0.82 | NLRP3 (0.65) | NLRP3AKR1B1ALOX15KMT2A | |
| SCHEMBL24077127 | 0.82 | NLRP3 (0.48) | NLRP3AKR1B1ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885AKR1B1 162/4885GPR139 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.